PDF下载 ( 1692 KB)
代谢相关脂肪性肝病微循环障碍与微血管系统的相关性
DOI: 10.3969/j.issn.1001-5256.2023.08.026
利益冲突声明：本文不存在任何利益冲突。
作者贡献声明：李安琪负责课题设计，资料分析，撰写论文；王锐负责修改论文；赵玉强、赵佩然参与收集及分析文献资料；杨婧负责拟定写作思路，指导撰写文章并最后定稿。
Research advances in the association between microcirculation disturbance and microvascular system in metabolic associated fatty liver disease
-
摘要: 代谢相关脂肪性肝病(MAFLD)被认为是一种多系统疾病，可导致多种肝外并发症，其中心血管疾病(CVD)是MAFLD患者最常见的死亡原因。MAFLD与其并发症有许多共同的代谢危险因素，通过炎症、内皮功能障碍、氧化应激、胰岛素抵抗和脂质代谢异常等机制，增加糖尿病、高血压、动脉粥样硬化、静脉血栓形成等的易感性，与MAFLD的病理之间存在复杂的相互作用，促进彼此的发生。在MAFLD进展过程中，肝脏微血管的各个部分都可能发生变化，导致肝脏微循环障碍，肝内微血管紊乱和微循环功能障碍是肝外并发症发展的关键，但MAFLD仍未像其他传统风险因素一样被重视。深入了解MAFLD中微血管系统病理改变与微循环障碍之间的联系，有助于MAFLD肝外并发症的机制研究和治疗，更重要的是让MAFLD患者更加重视肝脏以外的保健治疗。Abstract: Metabolic associated fatty liver disease (MAFLD) is considered a multisystem disease that can lead to multiple extrahepatic complications, among which cardiovascular disease (CVD) is the most common cause of death in MAFLD patients. MAFLD and its complications share many common metabolic risk factors, which increase the susceptibility to diabetes, hypertension, atherosclerosis, and venous thrombosis through the mechanisms such as inflammation, endothelial dysfunction, oxidative stress, insulin resistance, and abnormal lipid metabolism, and there is a complex interaction between such factors and the pathology of MAFLD, thereby promoting the occurrence of each other. During the progression of MAFLD, there might be changes in various parts of the liver microvasculature, resulting in hepatic microcirculation disturbance, and intrahepatic microvascular disturbance and microcirculation dysfunction are the key to the progression of extrahepatic complications, but MAFLD has not yet been taken seriously like other traditional risk factors. An in-depth understanding of the association between pathological changes of the microvasculature and microcirculation disturbance in MAFLD will help with the mechanism research and treatment of the extrahepatic complications of MAFLD, and more importantly, help MAFLD patients pay more attention to healthcare outside the liver.
-
Key words:
- Metabolic Associated Fatty Liver Disease /
- Microvessels /
- Microcirculation
-
[1] BOECKMANS J, ROMBAUT M, DEMUYSER T, et al. Infections at the nexus of metabolic-associated fatty liver disease[J]. Arch Toxicol, 2021, 95(7): 2235-2253. DOI: 10.1007/s00204-021-03069-1. [2] SAKURAI Y, KUBOTA N, YAMAUCHI T, et al. Role of insulin resistance in MAFLD[J]. Int J Mol Sci, 2021, 22(8): 4156. DOI: 10.3390/ijms22084156. [3] ESLAM M, SANYAL AJ, GEORGE J, et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology, 2020, 158(7): 1999-2014. e1. DOI: 10.1053/j.gastro.2019.11.312. [4] CHEN L, WU N, KENNEDY L, et al. Inhibition of secretin/secretin receptor axis ameliorates NAFLD phenotypes[J]. Hepatology, 2021, 74(4): 1845-1863. DOI: 10.1002/hep.31871. [5] TOKUSHIGE K, IKEJIMA K, ONO M, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020[J]. J Gastroenterol, 2021, 56(11): 951-963. DOI: 10.1007/s00535-021-01796-x. [6] BYRNE CD, TARGHER G. NAFLD: a multisystem disease[J]. J Hepatol, 2015, 62(1 Suppl): S47-S64. DOI: 10.1016/j.jhep.2014.12.012. [7] LOOMBA R, FRIEDMAN SL, SHULMAN GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease[J]. Cell, 2021, 184(10): 2537-2564. DOI: 10.1016/j.cell.2021.04.015. [8] XU M, XU HH, LIN Y, et al. LECT2, a ligand for tie1, plays a crucial role in liver fibrogenesis[J]. Cell, 2019, 178(6): 1478-1492. e20. DOI: 10.1016/j.cell.2019.07.021. [9] CATALDO I, SARCOGNATO S, SACCHI D, et al. Pathology of non-alcoholic fatty liver disease[J]. Pathologica, 2021, 113(3): 194-202. DOI: 10.32074/1591-951X-242. [10] BASSEGODA O, OLIVAS P, TURCO L, et al. Decompensation in advanced nonalcoholic fatty liver disease may occur at lower hepatic venous pressure gradient levels than in patients with viral disease[J]. Clin Gastroenterol Hepatol, 2022, 20(10): 2276-2286. e6. DOI: 10.1016/j.cgh.2021.10.023. [11] ZHOU R, FAN X, SCHNABL B. Role of the intestinal microbiome in liver fibrosis development and new treatment strategies[J]. Transl Res, 2019, 209: 22-38. DOI: 10.1016/j.trsl.2019.02.005. [12] KÖNIGSHOFER P, HOFER BS, BRUSILOVSKAYA K, et al. Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies[J]. Hepatology, 2022, 75(3): 610-622. DOI: 10.1002/hep.32220. [13] van der GRAAFF D, CHOTKOE S, DE WINTER B, et al. Vasoconstrictor antagonism improves functional and structural vascular alterations and liver damage in rats with early NAFLD[J]. JHEP Rep, 2022, 4(2): 100412. DOI: 10.1016/j.jhepr.2021.100412. [14] ALBILLOS A, de GOTTARDI A, RESCIGNO M. The gut-liver axis in liver disease: Pathophysiological basis for therapy[J]. J Hepatol, 2020, 72(3): 558-577. DOI: 10.1016/j.jhep.2019.10.003. [15] BAFFY G. Potential mechanisms linking gut microbiota and portal hypertension[J]. Liver Int, 2019, 39(4): 598-609. DOI: 10.1111/liv.13986. [16] RODRIGUES SG, MONTANI M, GUIXÉ-MUNTET S, et al. Patients with signs of advanced liver disease and clinically significant portal hypertension do not necessarily have cirrhosis[J]. Clin Gastroenterol Hepatol, 2019, 17(10): 2101-2109. e1. DOI: 10.1016/j.cgh.2018.12.038. [17] GARCÍA-LEZANA T, RAURELL I, BRAVO M, et al. Restoration of a healthy intestinal microbiota normalizes portal hypertension in a rat model of nonalcoholic steatohepatitis[J]. Hepatology, 2018, 67(4): 1485-1498. DOI: 10.1002/hep.29646. [18] KANG N. Mechanotransduction in liver diseases[J]. Semin Liver Dis, 2020, 40(1): 84-90. DOI: 10.1055/s-0039-3399502. [19] CHIN L, THEISE ND, LONEKER AE, et al. Lipid droplets disrupt mechanosensing in human hepatocytes[J]. Am J Physiol Gastrointest Liver Physiol, 2020, 319(1): G11-G22. DOI: 10.1152/ajpgi.00098.2020. [20] HO CM, HO SL, JENG YM, et al. Accumulation of free cholesterol and oxidized low-density lipoprotein is associated with portal inflammation and fibrosis in nonalcoholic fatty liver disease[J]. J Inflamm (Lond), 2019, 16: 7. DOI: 10.1186/s12950-019-0211-5. [21] STINE JG, NICCUM BA, ZIMMET AN, et al. Increased risk of venous thromboembolism in hospitalized patients with cirrhosis due to non-alcoholic steatohepatitis[J]. Clin Transl Gastroenterol, 2018, 9(3): 140. DOI: 10.1038/s41424-018-0002-y. [22] GABALLA D, BEZINOVER D, KADRY Z, et al. Development of a model to predict portal vein thrombosis in liver transplant candidates: the portal vein thrombosis risk index[J]. Liver Transpl, 2019, 25(12): 1747-1755. DOI: 10.1002/lt.25630. [23] ABDEL-RAZIK A, MOUSA N, SHABANA W, et al. De novo portal vein thrombosis in non-cirrhotic non-alcoholic fatty liver disease: a 9-year prospective cohort study[J]. Front Med (Lausanne), 2021, 8: 650818. DOI: 10.3389/fmed.2021.650818. [24] de GOTTARDI A, RAUTOU P E, SCHOUTEN J, et al. Porto-sinusoidal vascular disease: proposal and description of a novel entity[J]. Lancet Gastroenterol Hepatol, 2019, 4(5): 399-411. DOI: 10.1016/S2468-1253(19)30047-0. [25] de GOTTARDI A, SEMPOUX C, BERZIGOTTI A. Porto-sinusoidal vascular disorder[J]. J Hepatol, 2022, 77(4): 1124-1135. DOI: 10.1016/j.jhep.2022.05.033. [26] BALAKRISHNAN M, GARCIA-TSAO G, DENG Y, et al. Hepatic arteriolosclerosis: a small-vessel complication of diabetes and hypertension[J]. Am J Surg Pathol, 2015, 39(7): 1000-1009. DOI: 10.1097/PAS.0000000000000419. [27] PANDAY R, MONCKTON CP, KHETANI SR. The role of liver zonation in physiology, regeneration, and disease[J]. Semin Liver Dis, 2022, 42(1): 1-16. DOI: 10.1055/s-0041-1742279. [28] LI J, ZHANG X, TIAN J, et al. CX08005, a protein tyrosine phosphatase 1b inhibitor, attenuated hepatic lipid accumulation and microcirculation dysfunction associated with nonalcoholic fatty liver disease[J]. Pharmaceuticals (Basel), 2023, 16(1): 106. DOI: 10.3390/ph16010106. [29] WISSE E, BRAET F, SHAMI GJ, et al. Fat causes necrosis and inflammation in parenchymal cells in human steatotic liver[J]. Histochem Cell Biol, 2022, 157(1): 27-38. DOI: 10.1007/s00418-021-02030-8. [30] MATHIEU M, MARTIN-JAULAR L, LAVIEU G, et al. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication[J]. Nat Cell Biol, 2019, 21(1): 9-17. DOI: 10.1038/s41556-018-0250-9. [31] HERNÁNDEZ A, ARAB JP, REYES D, et al. Extracellular vesicles in NAFLD/ALD: from pathobiology to therapy[J]. Cells, 2020, 9(4): 817. DOI: 10.3390/cells9040817. [32] JIANG F, CHEN Q, WANG W, et al. Hepatocyte-derived extracellular vesicles promote endothelial inflammation and atherogenesis via microRNA-1[J]. J Hepatol, 2020, 72(1): 156-166. DOI: 10.1016/j.jhep.2019.09.014. [33] LIU XL, PAN Q, CAO HX, et al. Lipotoxic hepatocyte-derived exosomal microRNA 192-5p activates macrophages through Rictor/Akt/Forkhead box transcription factor O1 signaling in nonalcoholic fatty liver disease[J]. Hepatology, 2020, 72(2): 454-469. DOI: 10.1002/hep.31050. [34] XU M, XU H H, LIN Y, et al. LECT2, a Ligand for tie1, plays a crucial role in liver fibrogenesis[J]. Cell, 2019, 178(6): 1478-1492. e20. DOI: 10.1016/j.cell.2019.07.021. [35] YE L, CAO Z, LAI X, et al. Niacin Ameliorates hepatic steatosis by inhibiting De Novo lipogenesis via a GPR109A-Mediated PKC-ERK1/2-AMPK signaling pathway in C57BL/6 mice fed a high-fat diet[J]. J Nutr, 2020, 150(4): 672-684. DOI: 10.1093/jn/nxz303. [36] BARROW F, KHAN S, WANG H, et al. The emerging role of B cells in the pathogenesis of NAFLD[J]. Hepatology, 2021, 74(4): 2277-2286. DOI: 10.1002/hep.31889. [37] OGRESTA D, MRZLJAK A, CIGROVSKI BERKOVIC M, et al. Coagulation and endothelial dysfunction associated with NAFLD: current status and therapeutic implications[J]. J Clin Transl Hepatol, 2022, 10(2): 339-355. DOI: 10.14218/JCTH.2021.00268. [38] BRESLIN JW, YANG Y, SCALLAN JP, et al. Lymphatic vessel network structure and physiology[J]. Compr Physiol, 2018, 9(1): 207-299. DOI: 10.1002/cphy.c180015. [39] TAMBURINI B, FINLON JM, GILLEN AE, et al. Chronic liver disease in humans causes expansion and differentiation of liver lymphatic endothelial cells[J]. Front Immunol, 2019, 10: 1036. DOI: 10.3389/fimmu.2019.01036. [40] BURCHILL MA, FINLON JM, GOLDBERG AR, et al. Oxidized low-density lipoprotein drives dysfunction of the liver lymphatic system[J]. Cell Mol Gastroenterol Hepatol, 2021, 11(2): 573-595. DOI: 10.1016/j.jcmgh.2020.09.007. [41] DUONG CN, VESTWEBER D. Mechanisms ensuring endothelial junction integrity beyond VE-cadherin[J]. Front Physiol, 2020, 11: 519. DOI: 10.3389/fphys.2020.00519. [42] TAMBURINI B, FINLON JM, GILLEN AE, et al. Chronic liver disease in humans causes expansion and differentiation of liver lymphatic endothelial cells[J]. Front Immunol, 2019, 10: 1036. DOI: 10.3389/fimmu.2019.01036. [43] BURCHILL MA, FINLON JM, GOLDBERG AR, et al. Oxidized low-density lipoprotein drives dysfunction of the liver lymphatic system[J]. Cell Mol Gastroenterol Hepatol, 2021, 11(2): 573-595. DOI: 10.1016/j.jcmgh.2020.09.007. [44] SCHUPPAN D, SURABATTULA R, WANG XY. Determinants of fibrosis progression and regression in NASH[J]. J Hepatol, 2018, 68(2): 238-250. DOI: 10.1016/j.jhep.2017.11.012. [45] YILDIZ E, EL ALAM G, PERINO A, et al. Hepatic lipid overload triggers biliary epithelial cell activation via E2Fs[J]. Elife, 2023. DOI: 10.7554/eLife.81926. [46] YANG P, WANG Y, TANG W, et al. Western diet induces severe nonalcoholic steatohepatitis, ductular reaction, and hepatic fibrosis in liver CGI-58 knockout mice[J]. Sci Rep, 2020, 10(1): 4701. DOI: 10.1038/s41598-020-61473-6. [47] CLOUGH GF, CHIPPERFIELD AJ, THANAJ M, et al. Dysregulated neurovascular control underlies declining microvascular functionality in people with non-alcoholic fatty liver disease (NAFLD) at risk of liver fibrosis[J]. Front Physiol, 2020, 11: 551. DOI: 10.3389/fphys.2020.00551. [48] ADORI C, DARAIO T, KUIPER R, et al. Disorganization and degeneration of liver sympathetic innervations in nonalcoholic fatty liver disease revealed by 3D imaging[J]. Sci Adv, 2021, 7(30): eabg5733. DOI: 10.1126/sciadv.abg5733. [49] HURR C, SIMONYAN H, MORGAN DA, et al. Liver sympathetic denervation reverses obesity-induced hepatic steatosis[J]. J Physiol, 2019, 597(17): 4565-4580. DOI: 10.1113/JP277994. [50] CLOUGH GF, CHIPPERFIELD AJ, THANAJ M, et al. Dysregulated neurovascular control underlies declining microvascular functionality in people with non-alcoholic fatty liver disease (NAFLD) at risk of liver fibrosis[J]. Front Physiol, 2020, 11: 551. DOI: 10.3389/fphys.2020.00551. [51] PRANDONI P. Is there a link between venous and arterial thrombosis? A reappraisal[J]. Intern Emerg Med, 2020, 15(1): 33-36. DOI: 10.1007/s11739-019-02238-6. [52] ZUO R, YE LF, HUANG Y, et al. Hepatic small extracellular vesicles promote microvascular endothelial hyperpermeability during NAFLD via novel-miRNA-7[J]. J Nanobiotechnology, 2021, 19(1): 396. DOI: 10.1186/s12951-021-01137-3. -
本文二维码
计量
- 文章访问数: 211
- HTML全文浏览量: 68
- PDF下载量: 38
- 被引次数: 0
下载:
